COMP <GO>
RNXT vs ZYBT // DIVIDEND YIELD & FCF PAYOUT SAFETY
RenovoRx Inc. (NASDAQ) VS. Zhengye Biotechnology Holding Limited (Class A) (NASDAQ) • 15-METRIC TALLY: RNXT 3
— ZYBT 4
■ METRIC PARITY
LAST: $1.33 (-10.74%) • MKT CAP: $67.2M
dividend-safety
0.00%
LAST: $1.30 (-9.09%) • MKT CAP: $67.8M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNXT VS. ZYBT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RNXT | ZYBT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.90% | 20.50% | +50.40 | RNXT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -22.30% | -12.70 | ZYBT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.32% | 2.61% | -18.93 | ZYBT | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -34.80% | +214.80 | RNXT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.40 | 1.90 | -1.50 | ZYBT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.1 | 43.1 | +4.02 | RNXT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $67.2M | $67.8M | -$526.7K | ZYBT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RNXT REV | ZYBT REV | RNXT GROSS % | ZYBT GROSS % | RNXT FCF | ZYBT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.1M | $16.6M | 70.9% | 20.5% | -$11.0M | $1.8M |
| FY 2024 | $43.0K | $25.5M | 98.0% | 49.0% | -$9.1M | $3.8M |
| FY 2023 | $0 | — | — | — | -$10.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RNXT // BETA —
ZYBT // BETA —